Should we rewrite the natural history and prognosis of pulmonary Langerhans cell histiocytosis?

Sergio Harari [1,2] **and Davide Elia** [1]

[1]U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria – Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, MultiMedica, IRCCS, Milan, Italy. [2]Department of Clinical Sciences and Community Health, Università di Milano, Milan, Italy.

Corresponding author: Sergio Harari (sergio@sergioharari.it)

Shareable abstract (@ERSpublications)
The natural history and clinical prognosis of PLCH have changed, since its first description. A long-term follow-up is recommended in order to prevent the development of malignancies.
https://bit.ly/3KmGbNo

Cite this article as: Harari S, Elia D. Should we rewrite the natural history and prognosis of pulmonary Langerhans cell histiocytosis? *Eur Respir J* 2022; 59: 2200700 [DOI: 10.1183/13993003.00700-2022].

Received: 1 April 2022
Accepted: 14 April 2022

Pulmonary Langerhans cell histiocytosis (PLCH) is a diffuse cystic lung disease, involving several lung structures such as bronchioles, the interstitium and pulmonary vessels, to differing extents, leading to a variety of clinical phenotypes.